JP2013509432A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509432A5
JP2013509432A5 JP2012537122A JP2012537122A JP2013509432A5 JP 2013509432 A5 JP2013509432 A5 JP 2013509432A5 JP 2012537122 A JP2012537122 A JP 2012537122A JP 2012537122 A JP2012537122 A JP 2012537122A JP 2013509432 A5 JP2013509432 A5 JP 2013509432A5
Authority
JP
Japan
Prior art keywords
seq
residues
sequence
group
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054743 external-priority patent/WO2011053798A2/en
Publication of JP2013509432A publication Critical patent/JP2013509432A/ja
Publication of JP2013509432A5 publication Critical patent/JP2013509432A5/ja
Pending legal-status Critical Current

Links

JP2012537122A 2009-10-30 2010-10-29 ヘルペスウイルス感染を阻害するペプチド組成物および方法 Pending JP2013509432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28011209P 2009-10-30 2009-10-30
US61/280,112 2009-10-30
PCT/US2010/054743 WO2011053798A2 (en) 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016014209A Division JP6209228B2 (ja) 2009-10-30 2016-01-28 ヘルペスウイルス感染を阻害するペプチド組成物および方法

Publications (2)

Publication Number Publication Date
JP2013509432A JP2013509432A (ja) 2013-03-14
JP2013509432A5 true JP2013509432A5 (cg-RX-API-DMAC7.html) 2013-12-19

Family

ID=43923008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537122A Pending JP2013509432A (ja) 2009-10-30 2010-10-29 ヘルペスウイルス感染を阻害するペプチド組成物および方法
JP2016014209A Expired - Fee Related JP6209228B2 (ja) 2009-10-30 2016-01-28 ヘルペスウイルス感染を阻害するペプチド組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016014209A Expired - Fee Related JP6209228B2 (ja) 2009-10-30 2016-01-28 ヘルペスウイルス感染を阻害するペプチド組成物および方法

Country Status (6)

Country Link
US (2) US8802106B2 (cg-RX-API-DMAC7.html)
EP (1) EP2493911B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013509432A (cg-RX-API-DMAC7.html)
AU (1) AU2010313339B2 (cg-RX-API-DMAC7.html)
CA (1) CA2779459A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011053798A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34802B1 (fr) * 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
US9907844B2 (en) 2013-12-11 2018-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11390661B2 (en) 2016-06-27 2022-07-19 Aicuris Anti-Infective Cures Gmbh HCMV entry inhibitors
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111675752B (zh) * 2020-03-16 2023-07-07 成都奥达生物科技有限公司 一种冠状病毒膜融合抑制剂及其药物用途
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
US20240299587A1 (en) * 2021-02-24 2024-09-12 Pfizer Inc. Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof
CN115894708B (zh) * 2022-08-16 2023-10-10 青岛大学 一种人巨细胞病毒抗原表位嵌合肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335429C (en) * 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
EP0436537A4 (en) * 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US5831001A (en) 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9409962D0 (en) 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
CA2295933A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation Compounds and methods for treating and screening viral reactivation
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
FR2818279B1 (fr) * 2000-12-15 2005-02-25 Univ Paris Curie Peptide de la glycoproteine b de l'herpesvirus humain 7 utilisable notamment dans un test serologique elisa
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
WO2004058166A2 (en) * 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7491490B2 (en) 2004-05-12 2009-02-17 Wisconsin Alumni Research Foundation Cytomegalovirus disintegrin-like peptides
CA2645134A1 (en) 2006-03-08 2007-09-13 University Of Rochester Compositions and methods for detection and treatment of human herpesvirus (hhv)-6
CN101780277A (zh) 2009-01-15 2010-07-21 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的免疫原组成物及其使用方法
MA34802B1 (fr) * 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène

Similar Documents

Publication Publication Date Title
RU2016120641A (ru) Новые полипептиды
RU2492182C3 (ru) ГИДРОФОБНЫЕ, МОДИФИЦИРОВАННЫЕ, ПОЛУЧЕННЫЕ ИЗ preS ВИРУСА ГЕПАТИТА В (HBV) ПЕПТИДЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОНИКНОВЕНИЯ HBV И HDV
HRP20160798T1 (hr) Rekombinantni antigeni iz rsv
GB2598494A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
RU2009106118A (ru) Способ получения конъюгатов инсулино-подобного фактора роста i и поли(этиленгликоля)
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
JP2014508510A5 (cg-RX-API-DMAC7.html)
RU2009119597A (ru) Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
HRP20161710T1 (hr) Identifikacija, optimizacija i uporaba kriptičkih hla-a24 etiopa za imunoterapiju
JP2010508030A5 (cg-RX-API-DMAC7.html)
WO2011053798A3 (en) Peptide compositions and methods for inhibiting herpesvirus infection
RU2022100555A (ru) Новый пептид
RU2014140231A (ru) Антимикробные пептиды
NZ609474A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
RU2010154101A (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
RU2018112060A (ru) Слитый белок
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
RU2014101415A (ru) Модифицированные антибиотические пептиды с различным системным высвобождением
TW200716166A (en) Lawsonia intracellularis immunological proteins
GB2584210A (en) Peptides for inhibiting RAD51
WO2012140620A8 (en) Compositions for preventing and/or treating an infection by an hiv-1 virus
RU2005123050A (ru) Супер-антигенные фьюжн-белки и их использование
ZA202306485B (en) Peptides for the treatment of respiratory infections of viral origin